RINGSIDE

This is a Phase 2/3, randomized study in subjects with progressive desmoid tumors consisting of 2 parts. Part A is an open-label, dose regimen finding study; Part B is a double blind, placebo-controlled study utilizing the dose regimen selected in Part A.

Acronym:

RINGSIDE

ACTRN/NCT /ethics:

NCT04871282

Scientific title:

A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients With Progressing Desmoid Tumors

Sponsor / Cooperative group:

Ayala Pharmaceuticals, Inc